Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 128, Issue 4, Pages 1300-1316Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI95864
Keywords
-
Categories
Funding
- National Cancer Institute (NCI) [CA104838]
- Alex's Lemonade Stand Foundation Fellowship
- NCI [CA163910, CA190860, CA199553]
Ask authors/readers for more resources
Myc activation is a primary oncogenic event in many human cancers; however, these transcription factors are difficult to inhibit pharmacologically, suggesting that Myc-dependent downstream effectors may be more tractable therapeutic targets. Here, we show that Myc overexpression induces endoplasmic reticulum (ER) stress and engages the inositol-requiring enzyme ice (IRE1 alpha)/X-box binding protein 1 (XBP1) pathway through multiple molecular mechanisms in a variety of c-Myc- and N-Myc-dependent cancers. In particular, Myc-overexpressing cells require IRE1 alpha/X6P1 signaling for sustained growth and survival in vitro and in vivo, dependent on elevated stearoyl-CoA-desaturase 1 (SCO1) activity. Pharmacological and genetic XBP1 inhibition induces Myc-dependent apoptosis, which is alleviated by exogenous unsaturated fatty acids. Of note, SCD1 inhibition phenocopies IRE1 alpha RNase activity suppression in vivo. Furthermore, IRE1 alpha inhibition enhances the cytotoxic effects of standard chemotherapy drugs used to treat c-Myc-overexpressing Burkitt's lymphoma, suggesting that inhibiting the IRE1 alpha/XBP1 pathway is a useful general strategy for treatment of Myc-driven cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available